Moxifloxacin in Moxipey is active against a broad spectrum of gram-positive and gram-negative microorganisms, anaerobic, acid-resistant and atypical bacteria: Mycoplasmas pp.,
Chlamydias pp., Legionellas pp. Effective against bacterial strains that are resistant to beta-lactam antibiotics and macrolides.


Each 100 ml contains: moxifloxacin HCl BP eq. to moxifloxacin – 400 mg

Indications for use

  • Acute sinusitis
  • Exacerbation of chronic bronchitis
  • Community-acquired pneumonia
  • Uncomplicated and complicated skin and soft tissues (including infected diabetic foot)
  • Complicated intra-abdominal infection including polymicrobial infections (such as abstsedirovanie).

Mode of administration

For intravenous use. Constant infusion over 60 minutes.
If medically indicated the solution for infusion can be administered via a T-tube, together with compatible infusion solutions.
The recommended dose is 400 mg Moxispey, infused once daily.
Initial intravenous treatment may be followed by oral treatment with moxifloxacin 400 mg tablets, when clinically indicated.
In clinical studies most patients switched to oral therapy within 4 days for Community acquired pneumonia (CAP) or 6 days for Complicated skin and skin structure
infections(cSSSI). The recommended total duration of intravenous and oral treatment is 7 – 14 days for CAP and 7 – 21 days for cSSSI.
Renal/hepatic impairment:
No adjustment of dosage is required in patients with mild to severely impaired renal function or in patients on chronic dialysis i.e. haemodialysis and continuous ambulatory
peritoneal dialysis.
There is insufficient data in patients with impaired liver function.
Other special populations:
No adjustment of dosage is required in the elderly and in patients with low bodyweight.